- Home
- AARD vs REFI Comparison
AARD vs REFI Comparison
Compare AARD & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- REFI
- Stock Information
- Founded
- AARD 2017
- REFI 2021
- Country
- AARD United States
- REFI United States
- Employees
- AARD N/A
- REFI N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- AARD Health Care
- REFI Real Estate
- Exchange
- AARD Nasdaq
- REFI Nasdaq
- Market Cap
- AARD 277.9M
- REFI 255.6M
- IPO Year
- AARD 2025
- REFI 2021
- Fundamental
- Price
- AARD $11.22
- REFI $13.20
- Analyst Decision
- AARD Strong Buy
- REFI Strong Buy
- Analyst Count
- AARD 7
- REFI 3
- Target Price
- AARD $31.43
- REFI $20.00
- AVG Volume (30 Days)
- AARD 151.9K
- REFI 163.2K
- Earning Date
- AARD 11-14-2025
- REFI 11-04-2025
- Dividend Yield
- AARD N/A
- REFI 15.63%
- EPS Growth
- AARD N/A
- REFI N/A
- EPS
- AARD N/A
- REFI 1.84
- Revenue
- AARD N/A
- REFI $56,608,781.00
- Revenue This Year
- AARD N/A
- REFI $11.43
- Revenue Next Year
- AARD N/A
- REFI $4.75
- P/E Ratio
- AARD N/A
- REFI $7.17
- Revenue Growth
- AARD N/A
- REFI 2.58
- 52 Week Low
- AARD $4.88
- REFI $12.00
- 52 Week High
- AARD $19.58
- REFI $16.29
- Technical
- Relative Strength Index (RSI)
- AARD 39.08
- REFI 52.97
- Support Level
- AARD $10.65
- REFI $13.04
- Resistance Level
- AARD $17.94
- REFI $13.17
- Average True Range (ATR)
- AARD 0.95
- REFI 0.23
- MACD
- AARD -0.64
- REFI 0.10
- Stochastic Oscillator
- AARD 7.82
- REFI 87.10
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.